Importer of Controlled Substances Application: S and B Pharma, Inc., 9535-9536 [2021-02979]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices
must offer you the opportunity to appeal
the decision in accordance with the
agency’s procedures. If the agency has
received and acted upon or will act
upon a SAVE verification and you do
not believe the response is correct, you
may make an appointment for an inperson interview at a local USCIS office.
Detailed information on how to make
corrections or update your immigration
record, make an appointment, or submit
a written request to correct records
under the Freedom of Information Act
can be found on the SAVE website at
www.uscis.gov/save.
Tracy L. Renaud,
Senior Official Performing the Duties of the
Director, U.S. Citizenship and Immigration
Services.
[FR Doc. 2021–03149 Filed 2–12–21; 8:45 am]
BILLING CODE P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1226]
Certain Artificial Eyelash Extension
Systems, Products, and Components
Thereof; Commission Determination
Not To Review an Initial Determination
Granting Complainant’s Motion for
Leave To Amend the Complaint and
Notice of Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review an initial determination (‘‘ID’’)
(Order No. 10) of the presiding
administrative law judge (‘‘ALJ’’)
granting the complainant’s motion for
leave to amend the complaint and
notice of investigation.
FOR FURTHER INFORMATION CONTACT:
Lynde Herzbach, Office of the General
Counsel, U.S. International Trade
Commission, 500 E Street SW,
Washington, DC 20436, telephone (202)
205–3228. Copies of non-confidential
documents filed in connection with this
investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. General
information concerning the Commission
may also be obtained by accessing its
internet server at https://www.usitc.gov.
Hearing-impaired persons are advised
that information on this matter can be
obtained by contacting the
Commission’s TDD terminal on (202)
205–1810.
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:04 Feb 12, 2021
Jkt 253001
On
October 28, 2020, the Commission
instituted this investigation under
section 337 of the Tariff Act of 1930, as
amended, 19 U.S.C. 1337 (‘‘section
337’’), based on a complaint filed by
Lashify, Inc. of Glendale, California
(‘‘Complainant’’). See 85 FR 68366–67.
The complaint, as supplemented,
alleges a violation of section 337 based
upon the importation into the United
States, sale for importation, or sale after
importation into the United States of
certain artificial eyelash extension
systems, products, and components
thereof by reason of infringement of
certain claims of U.S. Patent Nos.
10,660,388 and 10,721,984 and U.S.
Design Patent Nos. D877,416 and
D867,664. The complaint also alleges
the existence of a domestic industry.
The notice of investigation names nine
respondents, including CVS Health
Corporation of Woonsocket, Rhode
Island and Ulta Beauty, Inc. of
Bolingbrook, Illinois. See id. The Office
of Unfair Import Investigations is also a
party to the investigation. See id.
On January 8, 2021, Complainant filed
a motion seeking leave to amend the
complaint and notice of investigation to
substitute: (1) CVS Pharmacy, Inc. in
place of CVS Health Corporation and (2)
Ulta Salon, Cosmetics & Fragrance, Inc.
in place of Ulta Beauty, Inc. No
responses to the motion were filed.
On January 22, 2021, the ALJ issued
the subject ID (Order No. 10) granting
Complainant’s motion for leave to
amend the complaint and notice of
investigation to reflect the substitutions.
Order No. 10 (Jan. 22, 2021). The subject
ID finds that Complainant’s motion is
supported by good cause pursuant to
Commission Rule 210.14(b) (19 CFR
210.14(b)) and that there is no prejudice
if the motion is granted. No party
petitioned for review of the subject ID.
The Commission has determined not
to review the subject ID. CVS Pharmacy,
Inc. and Ulta Salon, Cosmetics &
Fragrance, Inc. are named as
respondents in this investigation; and
CVS Health Corporation and Ulta
Beauty, Inc. are terminated from the
investigation.
The Commission vote for this
determination took place on February
10, 2021.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
SUPPLEMENTARY INFORMATION:
By order of the Commission.
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
9535
Issued: February 10, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–03059 Filed 2–12–21; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 731–TA–1059 (Third
Review)]
Hand Trucks and Certain Parts Thereof
From China
Determination
On the basis of the record 1 developed
in the subject five-year review, the
United States International Trade
Commission (‘‘Commission’’)
determines, pursuant to the Tariff Act of
1930 (‘‘the Act’’), that revocation of the
antidumping duty order on hand trucks
and certain parts thereof from China
would be likely to lead to continuation
or recurrence of material injury to an
industry in the United States within a
reasonably foreseeable time.
Background
The Commission instituted this
review on July 1, 2020 (85 FR 39584)
and determined on October 5, 2020 that
it would conduct an expedited review
(86 FR 2001, January 11, 2021).
The Commission made this
determination pursuant to section
751(c) of the Act (19 U.S.C. 1675(c)). It
completed and filed its determination in
this review on February 9, 2021. The
views of the Commission are contained
in USITC Publication 5159 (February
2021), entitled Hand Trucks and Certain
Parts Thereof from China: Investigation
No. 731–TA–1059 (Third Review).
By order of the Commission.
Issued: February 9, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021–02975 Filed 2–12–21; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–784]
Importer of Controlled Substances
Application: S and B Pharma, Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
1 The record is defined in § 207.2(f) of the
Commission’s Rules of Practice and Procedure (19
CFR 207.2(f)).
E:\FR\FM\16FEN1.SGM
16FEN1
9536
Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices
S&B Pharma, Inc. has applied
to be registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
listed below for further drug
information.
SUMMARY:
approved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–02979 Filed 2–12–21; 8:45 am]
BILLING CODE P
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 18, 2021. Such persons
may also file a written request for a
hearing on the application on or before
March 18, 2021.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
In
accordance with 21 CFR 1301.34(a), this
is notice that on December 18, 2020,
S&B Pharma, Inc., 405 S Motor Avenue,
Azusa, California 91702–3232, applied
to be registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
khammond on DSKJM1Z7X2PROD with NOTICES
4-Anilino-NPhenethyl-4Piperdine (ANPP).
Tapentadol ................
Drug
code
Schedule
8333
9780
II
II
The company plans to import
intermediate forms of Tapentadol (9780)
for further manufacturing prior to
distribution to its customers. The
company plans to import ANPP (8333)
to bulk manufacture other controlled
substances for distribution to its
customers. No other activity for this
drug code is authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or non-
VerDate Sep<11>2014
17:04 Feb 12, 2021
Jkt 253001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–780]
Bulk Manufacturer of Controlled
Substances Application: Bulk
Manufacturer of Marihuana: North Star
Holdings California, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
The Drug Enforcement
Administration (DEA) is providing
notice of an application it has received
from an entity applying to be registered
to manufacture in bulk basic class(es) of
controlled substances listed in schedule
I. DEA intends to evaluate this and other
pending applications according to its
regulations governing the program of
growing marihuana for scientific and
medical research under DEA
registration.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefor, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 19, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. To ensure proper handling of
comments, please reference Docket No.
DEA–780 in all correspondence,
including attachments.
SUPPLEMENTARY INFORMATION: The
Controlled Substances Act (CSA)
prohibits the cultivation and
distribution of marihuana except by
persons who are registered under the
CSA to do so for lawful purposes. In
accordance with the purposes specified
in 21 CFR 1301.33(a), DEA is providing
notice that the entity identified below
has applied for registration as a bulk
manufacturer of schedule I controlled
substances. In response, registered bulk
manufacturers of the affected basic
class(es), and applicants therefor, may
file written comments on or objections
of the requested registration, as
provided in this notice. This notice does
not constitute any evaluation or
DATES:
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
determination of the merits of the
application submitted.
The applicant plans to manufacture
bulk active pharmaceutical ingredients
(APIs) for product development and
distribution to DEA registered
researchers. If the application for
registration is granted, the registrant
would not be authorized to conduct
other activity under this registration
aside from those coincident activities
specifically authorized by DEA
regulations. DEA will evaluate the
application for registration as a bulk
manufacturer for compliance with all
applicable laws, treaties, and
regulations and to ensure adequate
safeguards against diversion are in
place.
As this applicant has applied to
become registered as a bulk
manufacturer of marihuana, the
application will be evaluated under the
criteria of 21 U.S.C. 823(a). DEA will
conduct this evaluation in the manner
described in the rule published at 85 FR
82333 on December 18, 2020, and
reflected in DEA regulations at 21 CFR
part 1318.
In accordance with 21 CFR
1301.33(a), DEA is providing notice that
on January 15, 2021, North Star
Holdings California, LLC, 69375 Ramon
Road, Cathedral City, California 92234,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substances:
Controlled substance
Marihuana Extract ........
Marihuana .....................
Drug
code
7350
7360
Schedule
I
I
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–02980 Filed 2–12–21; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–778]
Importer of Controlled Substances
Application: Noramco Coventry, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Noramco Coventry, LLC has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
SUMMARY:
E:\FR\FM\16FEN1.SGM
16FEN1
]]>Agencies
[Federal Register Volume 86, Number 29 (Tuesday, February 16, 2021)]
[Notices]
[Pages 9535-9536]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02979]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-784]
Importer of Controlled Substances Application: S and B Pharma,
Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
[[Page 9536]]
SUMMARY: S&B Pharma, Inc. has applied to be registered as an importer
of basic class(es) of controlled substance(s). Refer to Supplementary
Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before March 18, 2021.
Such persons may also file a written request for a hearing on the
application on or before March 18, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on December 18, 2020, S&B Pharma, Inc., 405 S Motor
Avenue, Azusa, California 91702-3232, applied to be registered as an
importer of the following basic class(es) of controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
4-Anilino-N-Phenethyl-4-Piperdine 8333 II
(ANPP).
Tapentadol............................ 9780 II
------------------------------------------------------------------------
The company plans to import intermediate forms of Tapentadol (9780)
for further manufacturing prior to distribution to its customers. The
company plans to import ANPP (8333) to bulk manufacture other
controlled substances for distribution to its customers. No other
activity for this drug code is authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-02979 Filed 2-12-21; 8:45 am]
BILLING CODE P
